Climb Bio (CLYM) Projected to Post Earnings on Wednesday

Key Points

• Q1 2026 report set for before the market opens on May 13, with analysts forecasting earnings of ($0.26) per share and expecting roughly ($1) EPS for the fiscal year after a recent quarterly miss.
• Shares jumped 18.2% to open at $11.45, trading near their 12‑month high, with a market cap of about $547 million and a negative PE reflecting its clinical‑stage biotech status.
• Analysts are largely positive—consensus rating is Buy with a $17.30 price target—and institutional investors now own roughly 69.76% of the stock following sizable recent purchases.

Climb Bio (NASDAQ:CLYM - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Climb Bio to post earnings of ($0.26) per share for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 7:00 AM ET.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.06). On average, analysts expect Climb Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Stock Up 18.2%

Shares of NASDAQ CLYM opened at $11.45 on Wednesday. The business's 50 day moving average price is $7.66 and its two-hundred day moving average price is $4.93. The company has a market cap of $546.97 million, a PE ratio of -12.87 and a beta of 0.02. Climb Bio has a twelve month low of $1.13 and a twelve month high of $11.49.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wedbush assumed coverage on Climb Bio in a research report on Thursday, March 5th. They set an "outperform" rating and a $12.00 price target on the stock. Oppenheimer boosted their price target on Climb Bio from $10.00 to $18.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 21st. HC Wainwright boosted their price target on Climb Bio from $11.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Climb Bio in a research report on Monday, April 20th. Finally, Robert W. Baird boosted their price objective on Climb Bio from $9.00 to $12.00 and gave the stock an "outperform" rating in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Climb Bio has an average rating of "Buy" and a consensus price target of $17.30.

Institutional Investors Weigh In On Climb Bio

Several institutional investors have recently made changes to their positions in the stock. MPM Bioimpact LLC bought a new stake in shares of Climb Bio in the fourth quarter valued at approximately $10,686,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Climb Bio by 265.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company's stock valued at $7,695,000 after buying an additional 1,396,722 shares during the period. ADAR1 Capital Management LLC boosted its stake in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company's stock valued at $5,730,000 after buying an additional 1,298,945 shares during the period. Sphera Funds Management LTD. boosted its stake in shares of Climb Bio by 114.4% in the fourth quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company's stock valued at $3,729,000 after buying an additional 497,410 shares during the period. Finally, Shay Capital LLC boosted its stake in shares of Climb Bio by 107.5% in the second quarter. Shay Capital LLC now owns 415,000 shares of the company's stock valued at $515,000 after buying an additional 215,000 shares during the period. 69.76% of the stock is currently owned by institutional investors.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.